6-bromo-3,8-dimethylimidazo[1,2-a]pyridine | 1216185-38-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-bromo-3,8-dimethylimidazo[1,2-a]pyridine
• CAS: 1216185-38-4
• 化学式: C₉H₉BrN₂
• mdl: MFCD14551610
• 分子量: 225.088
• InChiKey: PFBYJYBYJAZVCB-UHFFFAOYSA-N

物化性质

• 密度：
  1.53±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

反应信息

• 作为产物：
  描述：

  5-bromo-3-methyl-N-prop-2-ynylpyridin-2-amine 以 水 为溶剂， 生成 6-bromo-3,8-dimethylimidazo[1,2-a]pyridine
  参考文献：
  名称：

  [EN] ANTAGONIST OF ADENOSINE RECEPTORS
  [FR] ANTAGONISTE DES RÉCEPTEURS DE L'ADÉNOSINE

  摘要：

  The present invention relates to compounds of formula I shown below: wherein R1, R4, R5and R6are each as defined in the application. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or conditions in which adenosine A2a and/or A2b receptor activity is implicated, such as, for example, cancer.

  公开号：

  WO2023144559A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QU'AGENTS THÉRAPEUTIQUES
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2022108849A1

  公开（公告）日：2022-05-27

  The invention relates to compounds of structural formula I wherein A is independently N or C-R3, R1is selected from (C1to C6) alkyl, (C2to C6) alkenyl, (C2to C6) alkynyl, (C3to C10) cycloalkyl, (C5to C10) cycloalkenyl, (C2to C9) heterocycloalkyl, (C6to C10) aryl, and (C2to C9) heteroaryl, wherein each of the said (C1to C6) alkyl, (C2to C6) alkenyl, (C2to C6) alkynyl, (C3to C10) cycloalkyl, (C5to C10) cycloalkenyl, (C2to C9) heterocycloalkyl, (C6to C10) aryl, and (C2to C9) heteroaryl is optionally substituted with at least one R4group, and wherein said (C2to C9) heteroaryl is C-attached, and R2is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V) and formula (VI)..

  本发明涉及结构式I的化合物，其中A独立地为N或C-R3，R1选择自(C1到C6)烷基，(C2到C6)烯基，(C2到C6)炔基，(C3到C10)环烷基，(C5到C10)环烯基，(C2到C9)杂环烷基，(C6到C10)芳基，和(C2到C9)杂芳基，其中所述的(C1到C6)烷基，(C2到C6)烯基，(C2到C6)炔基，(C3到C10)环烷基，(C5到C10)环烯基，(C2到C9)杂环烷基，(C6到C10)芳基，和(C2到C9)杂芳基中的每一个都可以选择性地用至少一个R4基团取代，并且所述的(C2到C9)杂芳基是连接在碳上的，R2选择自公式(II)，公式(III)，公式(IV)，公式(V)和公式(VI)的群。
• Synthesis of Imidazo[1,2-<i>a</i>]pyridines: “Water-Mediated” Hydroamination and Silver-Catalyzed Aminooxygenation
  作者：Darapaneni Chandra Mohan、Sadu Nageswara Rao、Subbarayappa Adimurthy

  DOI：10.1021/jo3025303

  日期：2013.2.1

  Aqueous syntheses of methylimidazo[1,2-a]pyridines without any deliberate addition of catalyst are reported. Imidazo[1,2-a]pyrazine and imidazo[2,1-a]isoquinoline were also obtained in good yields under similar conditions. With acetonitrile as solvent, Ag-catalyzed intra-molecular aminooxygenation produced imidazo[1,2-a]pyridine-3-carbaldehydes in moderate to good yields.
• SUBSTITUTED INDOLE COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210253593A1

  公开（公告）日：2021-08-19

  Disclosed are compounds of Formula (I) or salts thereof, wherein Ring Het, R 1 , R 2 , R 3 , R 4 , R 5 , m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
• [EN] HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES POUR LE TRAITEMENT D'UNE INFECTION À ARENAVIRUS
  申请人：ARISAN THERAPEUTICS INC

  公开号：WO2018013430A2

  公开（公告）日：2018-01-18

  The invention relates to compounds of structural formula I, wherein A, D, and E are independently N or C-R3, G, H, and J are independently N or C, K is N or C-H, L is N, N-R3 or C-R3, and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R1 is selected from (C6 to C10) aryl, (C2 to C9) heteroaryl, and 5-indolyl, wherein each of the said (C6 to C10) aryl and (C2 to C9) heteroaryl is substituted with at least one R4a group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of (i), (ii), (iii), and (iv).